Zobrazeno 1 - 10 of 120 pro vyhledávání: '"Fedorak DK"'
1
Akademický článek
Intensified anti-TNF treatment downregulates the phenotype in ulcerative colitis: a 13-year prospective follow-up study.
Autor: Florholmen, Jon1,2, Goll, Rasmus1,2, Johnsen, Kay-Martin1,2 kay-martin.johnsen@unn.no
Publikováno v: Frontiers in Gastroenterology (Frontiers Media S.A.). 2024, p1-7. 7p.
Zobrazit plný text záznamu
2
Akademický článek
Albumin change predicts failure in ulcerative colitis treated with adalimumab.
Autor: Ishida, Natsuki1 (AUTHOR), Takahashi, Kenichi2 (AUTHOR), Asai, Yusuke2 (AUTHOR), Miyazu, Takahiro2 (AUTHOR), Tamura, Satoshi2 (AUTHOR), Tani, Shinya2 (AUTHOR), Yamade, Mihoko2 (AUTHOR), Iwaizumi, Moriya3 (AUTHOR), Hamaya, Yasushi2 (AUTHOR), Osawa, Satoshi1 (AUTHOR), Sugimoto, Ken2 (AUTHOR) sugimken@hama-med.ac.jp
Publikováno v: PLoS ONE. 1/2/2024, Vol. 19 Issue 1, p1-13. 13p.
Zobrazit plný text záznamu
3
Akademický článek
Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
Autor: Ma C; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Beilman CL, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN
Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2016 Apr; Vol. 22 (4), pp. 870-9.
Zobrazit plný text záznamu
4
Akademický článek
Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Autor: Ma C; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Beilman CL; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Huang VW; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Fedorak DK; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Wong K; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Kroeker KI; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Dieleman LA; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Halloran BP; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8., Fedorak RN; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T6G 2X8.
Publikováno v: Canadian journal of gastroenterology & hepatology [Can J Gastroenterol Hepatol] 2016; Vol. 2016, pp. 2079582. Date of Electronic Publication: 2016 Jul 11.
Zobrazit plný text záznamu
5
Akademický článek
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Autor: Ma C; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada., Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN
Publikováno v: Journal of clinical gastroenterology [J Clin Gastroenterol] 2015 Sep; Vol. 49 (8), pp. 675-82.
Zobrazit plný text záznamu
6
Akademický článek
Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
Autor: Ma C, Evaschesen CJ, Gracias G, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN
Publikováno v: Canadian journal of gastroenterology & hepatology [Can J Gastroenterol Hepatol] 2015 Aug-Sep; Vol. 29 (6), pp. 309-14. Date of Electronic Publication: 2015 Jun 12.
Zobrazit plný text záznamu
7
Akademický článek
Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
Autor: Huang VW; Department of Medicine, Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada; †Department of Laboratory Medicine and Pathology, Division of Medical Laboratory Science, University of Alberta, Edmonton, AB, Canada; and ‡Department of Surgery, Division of Surgery, University of Alberta, Edmonton, AB, Canada., Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN
Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2015 Jun; Vol. 21 (6), pp. 1359-67.
Zobrazit plný text záznamu
9
Akademický článek
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
Autor: Ma C; Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada., Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN
Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2014 Nov; Vol. 40 (9), pp. 1044-55. Date of Electronic Publication: 2014 Sep 03.
Zobrazit plný text záznamu
10
Akademický článek
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Autor: Ma C; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Huang V; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Fedorak DK; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Kroeker KI; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Dieleman LA; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Halloran BP; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Fedorak RN; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada. Electronic address: richard.fedorak@ualberta.ca.
Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2014 Nov; Vol. 8 (11), pp. 1454-63. Date of Electronic Publication: 2014 Jun 16.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje